

# Review: repetitive transcranial magnetic stimulation is of unknown effectiveness in people with depression

Declan M McLoughlin

Evid. Based Ment. Health 2003;6;118 doi:10.1136/ebmh.6.4.118

Updated information and services can be found at:

http://ebmh.bmj.com/cgi/content/full/6/4/118

These include:

**References** This article cites 3 articles, 1 of which can be accessed free at:

http://ebmh.bmj.com/cgi/content/full/6/4/118#BIBL

**Rapid responses** You can respond to this article at:

http://ebmh.bmj.com/cgi/eletter-submit/6/4/118

Email alerting service

Receive free email alerts when new articles cite this article - sign up in the box at

the top right corner of the article

**Topic collections** Articles on similar topics can be found in the following collections

Depressive disorder (401 articles)
Complementary medicine (1579 articles)

Neurology (1890 articles) Bipolar disorder (151 articles) Epidemiology (4602 articles)

Clinical trials (epidemiology) (9740 articles)

**Notes** 

## Review: repetitive transcranial magnetic stimulation is of unknown effectiveness in people with depression

Martin J, Barbanoj M, Schlaepfer T et al. Repetitive transcranial magnetic stimulation for the treatment of depression: systematic review and meta-analysis. Br J Psychiatry 2003;182:480-491.

QUESTION: Is repetitive transcranial magnetic stimulation more effective than sham treatment in people with depression?

Systematic review and meta-analysis.

## **Data sources**

The reviewers searched Medline, Embase, PsychLit, Cochrane Controlled Trials Register, Cochrane Depression, Neurosis and Anxiety review group trials register to 2002 and contacted authors for further information.

#### Study selection

Eligible studies were randomised controlled trials comparing repetitive transcranial magnetic stimulation versus a sham intervention in people with depressive disorder or bipolar disorder (in depressed phase), with or without psychosis (DSM-IV or ICD-10 criteria).

### **Data extraction**

Data were extracted using a standard form, and coded for methodological quality on the adequacy of randomisation, allocation concealment, intention to treat analysis, blinding of outcome assessment and confounding factors. The primary outcome measure was symptom severity (determined by Hamilton rating scale for depression or the Beck Depression Inventory).

14 studies met the inclusion criteria. The methodological quality of the studies was low. Mean age of participants ranged from 41.8 to 60.9 years. 13 studies included people with major depressive disorders only. 13 studies compared left-sided high frequency repetitive transcranial magnetic stimulation versus sham treatment. The remaining study compared right sided, low frequency repetitive transcranial magnetic stimulation versus sham treatment. Repetitive transcranial magnetic stimulation reduced depression on the Hamilton Depression scale compared with sham treatment after 2 weeks of treatment but not after a further 2 weeks (12 studies in metaanalysis; standardised mean difference after 2 weeks treatment: -0.35, 95% CI -0.66 to -0.04); (standardised mean difference after a further 2 weeks: -0.33, 95% CI -0.84 to +0.17). Outcomes on the Beck Depression Inventory were not significant at any time point.

### **Conclusions**

Existing trials are of low quality and provide inadequate evidence about effects of repetitive transcranial magnetic stimulation in people with depression.

#### COMMENTARY

Transcranial magnetic stimulation (TMS) is a relatively safe non-invasive method to focally stimulate the brain. Repetitive TMS (rTMS) induces sustained effects such that "fast" rTMS (>1 Hz) has an activating effect while "slow" (< 1 Hz) has an inhibitory effect. Using rTMS to modulate neuronal circuitry in neuropsychiatric disorders has attracted much research, particularly for treating depression.

This Cochrane Collaboration supported review is the most comprehensive meta-analysis of rTMS for depression to date. The authors included 14 studies, however, they acknowledge that many of the published trials are of variable quality. Most trials have few participants, unclear standards of randomisation and blinding, and use differing methods to administer rTMS to heterogeneous populations.

As with most previous reviews and meta-analyses, the general conclusion is that rTMS has a modest antidepressant effect compared to placebo rTMS but the evidence does not yet support routine use. One important limitation to the interpretation of this meta-analysis is that the authors have not taken into account that some placebo or "sham" forms of rTMS, in which a real coil is used angled away from the scalp, actually have an effect upon the underlying Thus the analysed trials should be further subdivided into those using activating or non-activating sham rTMS.

The conclusion is not too surprising, as the optimal parameters for administration of rTMS for depression have not been established. For example, which brain regions should be stimulated, for how long, and at what frequency? Clearly, more research is warranted into the novel antidepressant effects of rTMS. It is worth noting that something similar can be said of electroconvulsive therapy (ECT), probably the most powerful antidepressant treatment available and in use for 60 years. The possibility of rTMS as an alternative to ECT has also been proposed and some recent trial data suggest that rTMS may be as effective as ECT in non-psychotic major depression.

Declan M McLoughlin, PhD MRCPI MRCPsych Senior Lecturer Section of Old Age Psychiatry, Institute of Psychiatry London

- Loo CK, Taylor JL, Gandevia SC, McDarmont BN, Mitchell PB, Sachdev PS. Transcranial magnetic stimulation (TMS) in controlled treatment studies: are some "sham" forms active? *Biol Psychiatry* 2000; 47:325–331.
  Grunhaus L, Schreiber S, Dolberg OT, Polak D, Dannon PN. A randomized controlled comparison of electroconvulsive therapy and repetitive transcranial magnetic stimulation in severe and resistant nonpsychotic major depression. *Biol Psychiatry* 2003; 53:324–331.

Source of funding: Ministerio de Sanidad y Consumo, Instituto de Salud Carlos III, Spain.

For correspondence: J Martin. Centro , Cochrane Iberoamericano, Server d'Epidemiologia Clinica i Salut Pública, Hospital de la Santa Creu i Sant Pau. Universidad Autónoma de Barcelona UAB, Casa de Convalescència C/171 Sant Antoni Ma  ${\it Claret, Barcelona}$ 08041 Spain. jrodriguezma@ hsp.santpau.es